Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?
Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?
Emergent BioSolutions, Inc. (NYSE:EBS) shares surged higher Thursday after the company announced operational changes to stabilize its financial position and reported first-quarter financial results.
Emergent BioSolutions, Inc.（紐約證券交易所代碼：EBS）股價週四飆升，此前該公司宣佈了運營調整以穩定其財務狀況，並公佈了第一季度財務業績。
The Details:
細節：
Emergent reported quarterly earnings of 59 cents per share, which beat the analyst consensus estimate of losses of 83 cents by 171.08%.
Emergent公佈的季度每股收益爲59美分，比分析師普遍預期的83美分虧損高出171.08％。
Quarterly sales clocked in at $300.4 million, which beat the analyst consensus estimate of $224.5 million by 33.81% and represents an 82.84% increase from the same period last year.
季度銷售額爲3.004億美元，比分析師普遍預期的2.245億美元高出33.81％，比去年同期增長82.84％。
The company also announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities and restructures its enterprise workforce to improve its performance and profitability.
該公司還宣佈了其新運營計劃的下一階段，該計劃將整合業務，關閉多個製造設施並重組企業員工隊伍，以提高其業績和盈利能力。
Emergent will shut down both its Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility. The company will also reduce its workforce by 300 employees across all areas of the company, and eliminate approximately 85 positions that are currently vacant.
Emergent將關閉其巴爾的摩-灣景藥物製造工廠和馬里蘭州羅克維爾的藥品工廠。該公司還將在公司所有領域裁員300人，並裁撤目前空缺的大約85個職位。
The company expects savings of approximately $80 million when fully implemented. Costs associated with the restructuring plan are estimated to be approximately $18 million to $21 million and are expected to be primarily incurred in the second half of 2024.
該公司預計，全面實施後將節省約8000萬美元。與重組計劃相關的成本估計約爲1,800萬至2,100萬美元，預計將主要在2024年下半年產生。
Emergent raised its revenue guidance for 2024 to between $1 billion and $1.1 billion.
Emergent將其2024年的收入預期提高至10億至11億美元之間。
Related News: Enovix Stock Soars On Blockbuster Q1 Sales
相關新聞： Enovix 股價因第一季度銷量大漲而飆升
EBS Stock Prediction 2024:
2024 年 EBS 股票預測：
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
華爾街內外的股票研究分析師通常使用收益增長和基礎研究作爲估值和預測的一種形式。但是，許多交易者將技術分析作爲形成股價走勢預測模型的一種方式。
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Emergent BioSolutions, an investor could make an assessment about a stock's long term prospects using a moving average and trend line.
一些投資者通過趨勢來幫助預測他們認爲股票在未來某個時刻的交易走向。從Emergent BioSolutions來看，投資者可以使用移動平均線和趨勢線對股票的長期前景進行評估。
If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Emergent BioSolutions, the 200-day moving average sits at $3.04, according to Benzinga Pro, which is below the current price of $3.99. For more on charts and trend lines, see a description here.
如果他們認爲股票將保持在移動平均線上方（許多人認爲這是一個看漲信號），他們可以使用趨勢線將這種趨勢推斷到未來。根據Benzinga Pro的數據，Emergent BioSolutions的200天移動平均線爲3.04美元，低於目前的3.99美元。有關圖表和趨勢線的更多信息，請參閱此處的描述。
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
交易者認爲，當股票高於其移動平均線時，這是一個普遍看漲的信號，而當它跌破移動平均線時，則是一個更加消極的信號。投資者可以使用趨勢線做出有根據的猜測，如果情況保持穩定，股票以後可以在哪裏交易。
EBS Price Action: According to Benzinga Pro, Emergent BioSolutions shares closed 70.9% higher at $3.30 on Thursday.
EBS價格走勢：根據Benzinga Pro的數據，Emergent BioSolutions股價週四收盤上漲70.9％，至3.30美元。
Image: Gerd Altmann from Pixabay
圖片：來自 Pixabay 的 Gerd Altmann